Sign inJoin waitlistJoin the waitlist

Shilpa Gupta

Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center · Case Western Reserve University

Credentials: · · · ·

History

Cleveland Clinic
2019–Present

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
2009–2010
Medical College of Wisconsin - Milwaukee
2008–2009
Hematology and Medical Oncology
Georgetown University School of Medicine
2007–2008
Internal Medicine
Univ of Connecticut Health Center/John Dempsey Hospital
2004–2007
Lady Hardinge Medical College
1997–2001
RCH Government Hospital
2000–2001

Research

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Journal of Clinical Oncology · 2016 · 1,239 citations
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
New England Journal of Medicine · 2024 · 923 citations

Petros Grivas
49 papers
Neeraj Agarwal
31 papers
Rana McKay
26 papers · 5 as a resident
Mehmet Bilen
24 papers
Joaquim Bellmunt
23 papers
Vadim Koshkin
22 papers
Ali Khaki
21 papers · 2 as a fellow
Amanda Nizam
21 papers · 21 as a fellow
Ashish Kamat
21 papers
Matthew Galsky
19 papers
Yousef Zakharia
16 papers · 2 as a fellow
Matthew Milowsky
15 papers

Grants

Prognostic and Predictive Digital Tissue Image Assay for Prostate Cancer
National Cancer Institute · R01
PI · $3M · Emory University
2022–2027
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
National Cancer Institute · U54
Project lead · $295.3K · Cleveland Clinic Lerner Com-Cwru
2022–2027

Clinical trials

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Principal investigator · Recruiting · Phase 1
Shilpa Gupta, MD
2024–2027
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2022–2029
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Principal investigator · Terminated · Phase 2
Masonic Cancer Center, University of Minnesota
2017–2019
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Principal investigator · Completed · Phase 2
Masonic Cancer Center, University of Minnesota
2012–2018